Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related ...

Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely ...

It was in with the new and out with the old Jan. 3 as the gavel came down on the first session of the 119th U.S. Congress.

Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint ...

The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV ...

Biopharma companies secured $102.15 billion in funding in 2024, a 44% increase from $70.97 billion in the full-year 2023 and significantly higher than the $60.81 billion raised in 2022. December ...

Caseinolytic protease P (ClpP) is a conserved serine protease present in both bacteria and humans, essential for maintaining protein quality by degrading misfolded proteins.

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

Companies working in the field of women’s health have long struggled for funding, but as the number of these companies increase and new dedicated venture capital funds emerge, the conversation is ...

In a recently published study, researchers based at Université Paris-Saclay identified OXA-1186, a novel carbapenemase related to the previously known OXA-198 enzyme, in a clinical isolate of ...

The U.K. is embarking on the biggest overhaul of clinical trials regulations in 20 years in a bid to retake ground that was lost following Brexit, when the Medicines and Healthcare products Agency was ...

After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that targets TDP-43, a protein directly ...